Your session is about to expire
← Back to Search
Wearable Device
Apollo Device for Breast Cancer
N/A
Waitlist Available
Led By Margaret Q Rosenzweig
Research Sponsored by Margaret Quinn Rosenzweig
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Metastatic breast cancer diagnosis
Fatigue score of 4 or greater at last clinic visit
Must not have
Use of medications for serious mental illness
Use of Beta Blockers
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 8 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a wearable device called Apollo, which emits gentle vibrations, to help reduce fatigue and pain in patients with Metastatic Breast Cancer. The device works by sending calming signals to the brain through vibrations, aiming to reduce stress and improve energy.
Who is the study for?
This trial is for individuals with Metastatic Breast Cancer (MBC) who experience significant fatigue. Participants must have had a fatigue score of 4 or higher at their last clinic visit, be able to read and understand English, and not be on medications for serious mental illness or beta blockers.
What is being tested?
The Apollo Armband, a wearable device that emits vibrations similar to a FitBit, is being tested in this study. The goal is to see if it can reduce symptoms of fatigue and pain in patients with MBC through self-reported surveys and medical chart reviews.
What are the potential side effects?
Since the Apollo Armband uses vibrations, potential side effects may include discomfort where the armband touches the skin or an allergic reaction to its materials. However, specific side effects are not detailed as it's non-invasive.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My breast cancer has spread to other parts of my body.
Select...
I reported a fatigue level of 4 or higher at my last clinic visit.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am taking medication for a serious mental illness.
Select...
I am currently taking beta blockers.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Fatigue (FACT-F)
Change in Fatigue (PROMIS-Fatigue)
Secondary study objectives
Degree of Pain
Health Related quality of life (HRQOL)
Hospital Anxiety and Depression Scale (HADS)
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Apollo ArmbandExperimental Treatment1 Intervention
Armband that can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apollo Armband
2021
N/A
~30
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for breast cancer include surgery, chemotherapy, radiation therapy, hormone therapy, and targeted therapy. Surgery involves removing the tumor, while chemotherapy uses drugs to kill cancer cells.
Radiation therapy uses high-energy rays to destroy cancer cells, and hormone therapy blocks hormones that fuel certain cancers. Targeted therapy attacks specific molecules involved in cancer growth.
The Apollo device, which uses vibration-based sensory stimulation, aims to alleviate symptoms like fatigue and pain by modulating the nervous system. Understanding these mechanisms helps patients and doctors choose the most effective treatment plan, manage side effects, and improve quality of life.
Find a Location
Who is running the clinical trial?
Margaret Quinn RosenzweigLead Sponsor
Apollo Neuroscience, Inc.Industry Sponsor
4 Previous Clinical Trials
700 Total Patients Enrolled
Margaret Q RosenzweigPrincipal InvestigatorUniversity of Pittsburgh School of Nursing
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am taking medication for a serious mental illness.My breast cancer has spread to other parts of my body.I reported a fatigue level of 4 or higher at my last clinic visit.I am currently taking beta blockers.
Research Study Groups:
This trial has the following groups:- Group 1: Apollo Armband
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger